title: Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
abstract: BACKGROUND
  Altered fractionation radiotherapy (RT) improves locoregional control in head and neck cancer without aggravation of late adverse events. To improve successful larynx-preservation rates in patients with resectable, intermediate-volume hypopharyngeal cancer, a prospective trial of chemotherapy-enhanced accelerated RT was conducted.
  
  
  METHODS
  Patients with T2 to T4 hypopharyngeal cancer received 40 Gray (Gy)/4 weeks to the entire neck followed by boost RT administering 30 Gy/2 weeks (1.5 Gy twice-daily fractionation). Cisplatin and 5-fluorouracil were administered concomitantly only during boost RT.
  
  
  RESULTS
  Thirty-five patients were enrolled in this study. All patients completed this protocol as planned. After a median follow-up period for surviving patients of 59 months (24-90 months), overall survival and local control rates at 3 years were 91% (95% confidence interval, 81% to 100%), and 88% (79% to 99%), respectively. All surviving patients maintained normalcy of diets.
  
  
  CONCLUSIONS
  This regimen was feasible with encouraging oncological and functional outcomes.
authors.affiliation: Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan. mkawashi@east.ncc.go.jp
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Kawashima
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Hayashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Tahara
authors.forename: Satoko
authors.initials: S
authors.lastname: Arahira
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Minoru
authors.initials: M
authors.lastname: Sakuraba
authors.forename: Sadamoto
authors.initials: S
authors.lastname: Zenda
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D007150:Immunohistochemistry; D007830:Larynx / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D016879:Salvage Therapy; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D002945:Cisplatin; D005472:Fluorouracil